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Impact of renal transplantation on survival in end-stage renal
In the general population, obesity is defined as a body disease patients with elevated body mass index.
mass index (BMI) Ն30 kg/m 2 , and is associated with
Background. Cadaveric renal transplantation is associated higher rates of hypertension, diabetes, cardiovascular with a survival advantage compared with dialysis patients redisease, and premature death [1, 2] . Among renal transmaining on the renal transplantation waiting list, but this advanplant recipients, obesity either at the time of or after tage has not been confirmed in obese end-stage renal disease (ESRD) patients.
renal transplantation has been associated with shortened
Methods. Using data from the USRDS, we studied 7521 allograft and patient survival [3, 4] shown to be associated with improved survival among regression models were used to calculate adjusted, time-depenpatients on maintenance dialysis, compared to patients dent hazard ratios (HR) for time to death in a given patient who are non-obese [7] [8] [9] .
during the study period, controlling for renal transplantation, Because of the above observations, the survival benefit demographics and comorbidities (Form 2728).
Results. ents at the time of transplant, and analysis of cadaveric recipients censored living donor recipients at the time Therefore, hospitalization and mortality data may be incomplete during the first 90 days after dialysis initiation of transplant. Survival time was calculated as the time from the date for patients younger than 65, but starts immediately after transplant.
of the first listing for transplant until death, or latest available follow-up date. In contrast to the previous verThe file SAF.PATIENTS was used as the primary data set, including cause of renal disease (PDIS) and cause sions of USRDS that were coordinated by the University of Michigan, after the 1999 USRDS report and SAFs, and date of patient death. SAF.RXHIST was used to obtain follow-up dates. The file SAF.TXWAIT contains the USRDS was coordinated by the University of Minnesota. In these files, follow-up dates (the variable the date patients in the above cohort were first placed on the transplant waiting list. The file SAF.MEDEVID ENDDATE) were intentionally left blank in the file RXHIST after patients received transplants. In direct includes data from the Medical Evidence Form (2728). The file SAF.TXUNOS included information on transconsultation with the USRDS, we were instructed to substitute the most recent follow-up date in the database plant donor type, pre-transplant dialysis, previous transplant, and multiple organ transplants. Files were merged (6 November 2000) for missing follow-up dates for transplant patients (personal communication, Dr. A.J Collins using unique patient identifiers. Details on anthropometric measurements or nutritional parameters other than and Dr. S. Chen, January 2002, and later reiterated in the 2001 Researcher's Guide to the USRDS, www.usrds. serum albumin were unavailable. No information on patient medications was available (for the entire cohort of org). In order to account for potential biases, survival times were calculated using two methods. In the first patients) except for the use of pre-dialysis erythropoietin. The USRDS researcher's agreement specifically promethod, we did not remove patients from the category of listing for transplant if they were removed from this hibits patient contact or chart review.
All analyses were performed using SPSS 9.0 (SPSS, category at a later time, nor did we remove patients from the category of renal transplant recipient if they later Inc., Chicago, IL, USA). Files were merged and converted to SPSS files using DBMS/Copy (Conceptual experienced graft loss, in intent to treat fashion. This methodology was in accordance with all previous studies, Software, Houston, TX, USA). Statistical significance was defined as P Ͻ 0.05. Univariate analysis was perand was most comparable with previous results. How- ever, potential bias applies to that approach. Mortality under-represented and diabetics were over represented. Characteristics of the obese cohort are shown in Table 1 . is higher after graft loss, compared with a functioning allograft. Therefore, survival time also was calculated As shown, there were significant differences between patients who were transplanted and those who were not, censoring patients at the date of graft loss. We also pereven after patients were placed on the transplant waiting formed stratified analysis limited to patients with body list. Patients who were transplanted were more likely to mass indices Ն40 kg/m 2 in order to determine if there have started dialysis earlier (due to the waiting time was a critical threshold of BMI above which no benefit for renal transplant), older, have higher serum albumin of renal transplantation could be demonstrated. Hierarlevels, and less likely to be African American, have pechically well-formed models were used for assessment ripheral vascular disease, or have BMI Ն35.8 kg/m 2 . For of interaction terms in all models. the obese cohort, the mean time from listing to transplantation was 0.89 Ϯ 0.77 (range 0.1 to 3.5) years for RESULTS cadaveric transplant recipients. Mean follow-up times Of 348,615 patients who initiated ESRD therapy in (in years) for both the obese and non-obese cohort are the USRDS database from April 1, 1995 to June 29, given in Table 2 . 1999, 43,707 were subsequently entered on the renal Figure 2 shows the distribution of BMI for the entire transplant waiting list, and of these, 40,493 were entered cohort of wait-listed patients (N ϭ 40,493) over the years on the waiting list on or after April 1, 1995. Of these, of the study. The increase in BMI by year was statistically 88% had sufficient information from the medical evisignificant in linear regression analysis (beta for year dence form (2728) to calculate BMI. Figure 1 shows the of first ESRD service ϭ 0.18, P Ͻ 0.001). BMI after strategy for patient extraction for the study population.
presentation to ESRD was only available for patients The mean date of first ESRD service was January 14, who received transplants, and this information was from 1997. The mean transplant date was December 25, 1997, the time of transplant. BMI could not be calculated for and the most recent transplant date was November 16, 57.9% of transplant recipients at the time of transplant 1999. The study had 51 months of accrual and 29 months due to missing data. However, for those who had comof additional follow-up. Compared to patients who did plete data, 35.2% had an increase in BMI from the time not have known BMI, patients with known BMI were of presentation to ESRD to the time of transplant, and 64.8% had a decrease in BMI. Of the transplant recipiof similar age and gender, but African Americans were Data given as the % of total (counts) or mean Ϯ standard deviation. ESRD is end-stage renal disease. Exclusion criteria (as per Methods section) were patients transplanted without preceding dialysis, or organs other than kidneys and they were excluded from analysis.
a History of condition within the past ten years or value at initiation of treatment for end stage renal disease b Adjusted odds ratio in logistic regression for association with receipt of renal transplant during the study period (Odds ratios above one reflect positive association with renal transplantation) ents with BMI Ն30 kg/m 2 at the time of ESRD, only significantly reduced risk of mortality for both recipients of solitary cadaver kidneys (61%) and of living donor 12.5% for whom data were available had BMI Ͻ30 kg/m 2 at the time of transplant, and were included in the obese kidneys (77%) in the obese cohort. In the non-obese cohort, the adjusted hazard ratio for cadaveric renal cohort. Because of the large percentage of patients with missing data, we did not perform a statistical analysis transplantation was identical to that for the obese cohort, but with narrower confidence intervals (0.39, 95% CI, using BMI at the time of transplant. Table 2 shows death rates for the study population, 0.35 to 0.43, P Ͻ 0.0001).
Of the obese cohort, 213 (9.4%) of patients transby all patients on the waiting list and by renal transplant recipients. After cadaveric renal transplantation, patient planted experienced graft loss after transplantation during the study period. Analysis using the same methods survival rates at one and three years were 95% and 90.9%, respectively. Table 3 shows the results of Cox and covariates also was performed censoring patients at the date of graft loss, to account for potential bias. In regression analysis of factors associated with patient mortality, analyzing solitary cadaveric renal transplantathis analysis, the adjusted hazard ratio for cadaveric renal transplantation in the obese cohort was 0.35 (95% CI, tion as a segmented time-dependent variable, adjusted for age, race, cause of ESRD, year of first dialysis, pres-0.29 to 0.42; P Ͻ 0.0001. Similar analysis was not performed for living donor transplant recipients, since the ence of congestive heart failure, and serum albumin level. As shown, renal transplantation was associated with a rates of graft loss were much lower than for cadaveric N ϭ 31,014) , stratified by year of first ESRD service. The majority of outliers had BMI Ն40 kg/m 2 . There was a significant increase in mean BMI over the time of the study period (in linear regression, beta for year of first ESRD ϭ 0.18, P Ͻ 0.001). The numbers to the right of outliers are USRDS ID numbers used for merging files, and cannot be used to identify patients. Multivariable analysis (by Cox non-proportional hazards regression) of factors associated with obesity in patients placed on the renal transplant waiting list, 1 April 1995 to 29 June 1999. Only variables significant in the final model (P Ͻ 0.05 by Cox regression analysis) are shown. Abbreviations are: AHR, adjusted hazard ratio for mortality; CHF, congestive heart failure; 95% CI, 95% confidence intervals; ESRD, end-stage renal disease; CHF, cardiac failure; PVD, peripheral vascular disease listed as a comorbidity on form 2728. a Analysis for CR: censored living donor recipients at the time of transplant; analysis for LR, censored cadaveric recipients at the time of transplant b The time-dependent covariate, for renal transplantation: 1 after the time of renal transplantation, 0 else c Adjusted hazard ratio for all-cause mortality. Hazard ratios greater than one reflect a positive association with mortality recipients. For the non-obese cohort, the corresponding tis, and malignancy at 2.7% each. In the first two months after transplant, six obese transplant recipients died. The hazard ratio was 0.33 (95% CI 0.30 to 0.37, P Ͻ 0.0001).
In the analysis limited to patients with BMI Ն41 kg/m 2 leading cause of death in obese transplant recipients was sepsis due to peritonitis (33%), with 17% of causes of (N ϭ 458), renal transplantation was no longer significantly associated with mortality (adjusted hazard ratio, death listed as blank or unknown, with other causes of death evenly distributed between atherosclerotic heart 0.47, 95% CI 0.17 to 1.25, P ϭ 0.13). For patients with a BMI Ն30 kg/m 2 up to 40 kg/m 2 , renal transplantation disease, cardiomyopathy, and malignancy. Among waitlisted patients who did not receive transplants during was significantly associated with lower mortality compared with remaining on the renal transplant waiting list.
the study, causes of death were missing or unknown in 33.3% of patients. The leading specified causes of death Among all renal transplant recipients, 46.8% of causes of death were blank or unknown. The leading specified were cardiac arrest, cause unknown (19.1%), acute myocardial infarction (9.3%), sepsis, other (6.8%), cardiac causes of death were cardiac arrest, cause unknown (9%), septicemia, non-specified (9%), acute myocardial arrhythmia (4.6%), stroke (3.3%), sepsis due to peripheral vascular disease/gangrene (2.2%), and sepsis due to infarction (4.3%), and pulmonary embolism (3.2%), followed by cardiomyopathy, stroke, sepsis due to peritoniperitonitis (2.1%).
DISCUSSION
appear to be in the best interest of obese ESRD patients to undergo renal transplantation. The present study shows that obese patients with
The reasons for an apparent survival benefit of renal ESRD have improved survival after renal transplantatransplantation have already been discussed [9] . The tion compared with remaining on the renal transplant demonstration of a benefit of renal transplantation in waiting list. A statistically significant benefit was seen obese patients with ESRD underscores the importance for obese recipients of both cadaveric and living donor of comparing high-risk groups not just with other renal kidneys, similar to the benefit of renal transplantation transplant recipients, but also with similar patients on previously shown for the entire population of patients the renal transplant waiting list. Such an approach had on the renal transplant waiting list [9] . It is remarkable been used previously for ESRD patients with hepatitis that the benefit of renal transplantation applied to all C [13], recipients of marginal donor kidneys [14] , and but the most morbidly obese patients on the waiting list diabetic recipients of combined kidney-pancreas trans-(those with BMI Ն41 kg/m 2 ).
plants [15] . It is clearly important for providers and patients alike
The limitations of this study are common to all retroto know the relative prognosis for obese transplant recipspective analyses of databases. Selection bias could have ients compared with non-obese transplant recipients.
arisen because of misclassification errors or missing data. However, it is perhaps more relevant to individual paEven after placement on the renal transplant waiting tients to know the prognosis of such patients after renal list, selection bias still occurred in the renal transplant transplantation compared with remaining on dialysis.
process, similar to previous studies [8, 16] . The methods Weight loss is recommended for potential transplant canof adjustment and stratification used in the present study didates who are obese, and in fact the majority of transare similar to those used in previous studies, with the plant recipients for whom data were available did achieve added advantage of comorbidity and laboratory data a decrease in BMI at the time of transplant, although from the Medical Evidence Form, which has not preonly 12.5% achieved a BMI of Յ30 kg/m 2 . However, viously been used in such analyses. However, higher many times weight loss does not achieve the desired BMI was independently associated with mortality in the goals. Given the significant increase in BMI among papresent analysis, indicating that there were still subcatetients on the renal transplant waiting list over time docugories of BMI that affected mortality differently in this mented in this study, the importance of elevated BMI population (that is, morbidly obese vs. obese), in contrast in renal transplantation will likely increase.
to the relationship seen in all chronic dialysis patients Because obesity is perceived as a negative factor in [6] [7] [8] . Information bias could have arisen from case selecboth listing and receipt of renal transplantation, it could tion, especially given the necessary exclusion of most be argued that obese candidates for renal transplantation transplant recipients during the years studied. Our study had to be healthier than non-obese candidates to receive confirmed that survival for both patients on the transrenal transplantation. However, the findings of the presplant waiting list and transplant recipients improved over ent study are strengthened by the inclusion of baseline time in comparison with the previous study of Wolfe et comorbidity data, which the study of Wolfe et al could al [10] , and consistent with other studies [17, 18] . In not assess due to recent changes in the Medical Evidence addition, demographic characteristics and mortality rates Form (2728) [10] . This suggests that the apparent survival in our study were comparable to previously published benefit of renal transplantation in obese ESRD patients reports, given differences in the population and years was not due to selection bias. The magnitude of the studied. Our study was limited by the lack of complete apparent survival benefit of renal transplantation for data in many of the fields, particularly for height and obese ESRD patients and non-obese ESRD patients apweight to calculate BMI. However, the study still obpears to be similar, according to the present study. Many tained BMI for more than 75% of all US ESRD patients transplant professionals have been reluctant to offer during that period, from whom the study population was transplantation to obese candidates for fear of surgical extracted. The study design allowed adequate followcomplications after transplant. The high rate of infecup after renal transplantation to avoid survival bias in tious death after transplant in obese recipients in the comparison to wait-listed patients. present study is consistent with the findings of MeierIt is possible that exclusion of transplant recipients Kriesche, Arndorfer and Kaplan, who found that obesity who did not have dialysis prior to transplantation or who was most strongly associated with infectious death after underwent transplantation without enrollment on the transplant [4] . Despite this, due to the high rate of cardiorenal transplant waiting list further underestimated the vascular death among patients on the renal transplant number of transplant recipients, similar to the techniques waiting list, renal transplantation offered a net survival of Wolfe et al [10] and Ojo et al [15] . Such patients had advantage for these patients. Therefore, although results no survival times prior to transplantation for comparison. Wolfe et al (in both of the previous studies) emphasized for individual patients can never be predicted, it would
